LogicBio Therapeutics (LOGC) Misses Q2 EPS by 50c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
EPS Growth %: +42.9%
Financial Fact:
Sales, general and administrative: 167.9K
Today's EPS Names:
CFFI, ZGN, SSNC, More
EPS Growth %: +42.9%
Financial Fact:
Sales, general and administrative: 167.9K
Today's EPS Names:
CFFI, ZGN, SSNC, More
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q2 EPS of ($0.50).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- JPMorgan Downgrades Ultrapar Holding (UGP) to Neutral
- JPMorgan Downgrades Ultrapar Participacoes SA (UGPA3:BZ) (UGP) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
